Streetbeat News

Products Services

ENSC

Ensysce Biosciences has engaged Alacrita Consulting to aid in the expansion of the use of TAAP and MPAR®, as well as the rapid development and commercialization of Ensysce's next generation opioids.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 12:08 pm

HUMA

Humacyte has completed enrollment in its Phase 2/3 clinical trial for the Human Acellular Vessel (HAV) for vascular trauma repair. This marks a significant milestone in the development of the HAV, which could potentially revolutionize the field of vascular surgery.

Portfolio Pulse from Bill Haddad

July 26, 2023 | 12:04 pm

SDC

SmileDirectClub (SDC) has announced the opening of eight new SmileShops in the UK and Ireland. This expansion is part of the company's ongoing efforts to increase its global footprint.

Portfolio Pulse from Bill Haddad

July 26, 2023 | 12:02 pm

INZY

Inozyme Pharma, Inc. (NASDAQ:INZY) has announced a regulatory update for its global development strategy of INZ-701 for the treatment of ENPP1 Deficiency. The company has finalized its pediatric pivotal trial design with PPi, a natural inhibitor of mineralization, as a primary endpoint in the U.S. and a co-primary endpoint in the EU. The company's updated cash runway is expected to fund cash flow requirements into Q1 2025.

Portfolio Pulse from Charles Gross

July 26, 2023 | 11:52 am

STBX

Starbox Group Holdings Ltd. (NASDAQ:STBX) has announced the launch of 'StarBoxGPT', an AI content creation platform aimed at providing services to Southeast Asia customers. The platform incorporates multimodal functions.

Portfolio Pulse from Charles Gross

July 26, 2023 | 11:43 am

BA

Boeing has announced that it is transitioning its 737 program to produce 38 planes per month and aims to reach 50 per month in the 2025/2026 timeframe. The company still expects to deliver 400-450 airplanes this year.

Portfolio Pulse from Bill Haddad

July 26, 2023 | 11:31 am

ATHE

An Independent Data Monitoring Committee has recommended that Alterity Therapeutics' ATH434-201 Phase 2 study in early-stage Multiple System Atrophy should continue as planned. The trial is expected to complete enrollment in Q3 2023, with top-line data expected by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 10:58 am

MRK

MRNA

Merck and Moderna have initiated a Phase 3 study evaluating V940 (mRNA-4157) in combination with KEYTRUDA for adjuvant treatment of patients with resected high-risk melanoma. The first patients are now enrolling in Australia.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 10:51 am

META

Meta Platforms Inc.'s new app Threads has introduced a chronological following feed, similar to Twitter's implementation. This feature was one of the most requested by users and is now available on iOS and Android versions of the app. Threads has also added AI-powered translation and new ways to filter notifications. This move by Meta may intensify the ongoing rivalry with Twitter.

Portfolio Pulse from Rounak Jain

July 26, 2023 | 10:35 am

TSLA

Tesla has initiated a recall for 1,337 Model S, X, Y vehicles due to misaligned front cameras. This could potentially affect the company's reputation and sales in the short term.

Portfolio Pulse from Charles Gross

July 26, 2023 | 10:25 am